An interventional study of CGuard Carotid Stent implantation in Carotid Artery Stenosis, sponsored by InspireMD. Active, not recruiting at 18 sites in 2 countries. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by InspireMD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Carotid Stenosis with a site in United States — 6 open to participants now, 13 under way, none of them phase 3. Carotid Stenosis · United States.
Among the 84 studies in Carotid Stenosis with a site in United States, this one is the 12th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2021, is one of 29 with no phase, reaches primary completion later than 1 of the 12 other live ones, and was the 75th registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →6 of the 84 studies in Carotid Stenosis with a site in United States are open now. Recruiting first, the newest first:
InspireMD · Sites in United States
Ages 18–79
Mayo Clinic · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–89 · Healthy volunteers
University of California, San Diego · Sites in United States
Ages 18+
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 65+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 7 · Phase 4 5
First in 1993; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 317 is above the median of 102 across 192 interventional studies indexed under Carotid Stenosis.
Median enrollment 69 across the 53 interventional studies, 114 across the 31 observational. Of the 60 that completed or were terminated, 22 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 84 have an industry lead sponsor. The 10 most frequent:
InspireMD is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
InspireMD has 3 studies filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Carotid Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851389Vibrant Medical Ltd.A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies | 2027-03 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
| NCT05465122Mayo ClinicCREST-2 Long-term Observational Extension Study | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 84 studies in Carotid Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this pivotal study is to evaluate the safety and efficacy of the CGuard™ Carotid Stent System in the treatment of carotid artery stenosis in symptomatic and asymptomatic patients undergoing carotid artery stenting (CAS) to a performance goal developed from published CAS literature.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject is diagnosed with carotid artery disease treatable with carotid artery stenting and is considered high risk for carotid endarterectomy (CEA) as evidenced by:
Symptomatic carotid stenosis ≥ 50%. Symptomatic is defined as amaurosis fugax, transient ischemia attack () or stroke within the last 6 months ipsilateral to the side of the stenosis.
Or
Co-Morbidity High Risk Conditions for CEA, i.e., meets one or more of the following criteria:
OR
High Anatomical Risk for CEA, i.e., meets one or more of the following criteria:
10. Angiographic General Inclusion Criteria, i.e., meets all the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single experimental arm compared vs. objective performace goal
Device: CGuard Carotid Stent implantation
Implantation of CGuard carotid stent in the eligible patients
Also known as: Carotid stenting
Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure
The primary endpoint is the composite of the following: * Incidence of the following Major Adverse Events: Death (allcause mortality), all Stroke, and Myocardial Infarction (DSMI) through 30-days post-index procedure, based on Clinical Events Committee (CEC) adjudication OR * Ipsilateral stroke from 31-365 day follow-up, based on Clinical Events Committee (CEC) adjudication.
Time frame: From index procedure to 1 year follow up
Incidence of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years
Incidence of the following composite of Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.
Time frame: From index procedure to 3 years follow up
Incidence of particular components of DSMI through discharge, 30 days, 6 months, and yearly follow ups till 3 years
Incidence of each individual component of the Major Adverse Events: Death (all-cause mortality), all Stroke, and Myocardial Infarction (DSMI) through discharge, 30-days, 6-months, and 1-,2-,3-year follow-up, based on Clinical Events Committee (CEC) adjudication.
Time frame: From index procedure to 3 years follow up
Incidence of ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.
Ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.
Time frame: From index procedure to 3 years follow up
Incidence of major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.
Major ipsilateral stroke through discharge, 30 days, 6 months and 1-, 2-, 3-year follow-up.
Time frame: From index procedure to 3 years follow up
Incidence of In-stent Restenosis (ISR) > 70% in ultrasound evaluation
Incidence of In-stent Restenosis (ISR) \> 70%. ISR \> 70% is defined as PSV \> 300 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.
Time frame: At 1-, 2-, 3-year post-index procedure follow-up
Incidence of In-stent Restenosis (ISR) > 50% in ultrasound evaluation
Incidence of In-stent Restenosis (ISR) \> 50%. ISR \> 50% is defined as PSV \> 220 cm/s associated with stent, or vessel occlusion based on transcervical duplex ultrasound through 1-, 2-, 3-year follow-up. Based on Imaging Core Laboratory assessment.
Time frame: At 1-, 2-, 3-year post-index procedure follow-up
Incidence of target lesion revascularization
Incidence of Target Lesion Revascularization (TLR) through 1-,2,3-year follow-up. TLR is defined as clinically driven revascularization procedure of the original treatment site, including angioplasty, stenting, endarterectomy, or thrombolysis, performed to open or increase the luminal diameter within the stented lesion or within 5 mm proximal or distal to the index stent.
Time frame: At 1-, 2-, 3-year post-index procedure follow-up
Composite of Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events
Ipsilateral stroke, stent thrombosis, cardiovascular death or other device related clinical events from discharge up to 1-,2- and 3-year follow-up.
Time frame: From index procedure to 3 years follow up
Composite of DSMI through 30 days or ipsilateral stroke 31 - 365 days post-index procedure for subjects that adhere to antiplatelet pharmacology.
Primary endpoint for subjects that adhere to antiplatelet pharmacology.
Time frame: From index procedure to 1 year follow up
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Jul 2021 to primary completion in Jul 2022, 12 months.
Of 62 interventional studies with no phase under Carotid Stenosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InspireMD